“After 35 years of marriage, my heart still sings when I look at her,” Philip said. “My cancer was much worse on Linda than it was on me, and her cancer was worse on me than it was on her. Whichever one of us was sick, the other one filled in the gaps. But that’s the way we normally live our lives. Whatever one needs, the other one provides.”

Philip’s pancreatic cancer was detected in early 2024 during an unrelated MRI of his kidneys. Arsen Osipov, MD, medical director of the Pancreatic Cancer Multidisciplinary Clinic and Multidisciplinary Cancer Programs and Integration at Cedars-Sinai, Philip’s oncologist, said it was a stroke of luck.

“He was diagnosed at a curable stage, before the cancer had spread,” Osipov said. “Only 10 to 20% of patients with pancreatic cancer are diagnosed this early.”

Philip was one of the first patients to visit the multidisciplinary clinic, where in a single day he met with medical oncologists, radiation oncologists, surgeons, gastroenterologists and other experts, and agreed on a treatment plan: four months of chemotherapy, followed by radiation and a complicated surgery called a Whipple procedure.

“This is a complex operation where we remove what’s called the head of the pancreas, the first part of the small intestine, the gallbladder and the bile duct,” said Nicholas Nissen, MD, director of Hepatobiliary and Pancreatic Surgery. “After removal, these structures are reattached to restore normal function.”

This procedure once required large incisions, but because radiation and chemotherapy successfully shrank Philip’s tumor, Nissen was able to perform the procedure robotically.

“This allows us to make smaller incisions, with lower risk of complications and a shorter recovery time for the patient,” Nissen said.

After four days in the hospital and two more months of chemotherapy, Philip was declared cancer-free in June.

But the couple had just a few days to celebrate.

Less than a week after Philip learned he was cancer-free, Linda was diagnosed with breast cancer after undergoing a routine mammogram.

“As a health system, we focus on screening and are always developing new ways to detect cancer early,” said Robert Figlin, MD, interim director of Cedars-Sinai Cancer. “For both of these patients, early detection was key to the best possible outcome.”

Still, the diagnosis was a bit of a shock to Philip and Linda.

“It was sort of unbelievable,” Linda said. “But we had been through the whole process with Phil, and his surgery was much more serious than mine, and he did so well that I felt much more comfortable.”

And she, too, was lucky, said Armando Giuliano, MD, director of Breast Surgical Oncology at Cedars-Sinai Cancer and Linda’s surgeon.

“She had a screen-detected cancer that has no symptoms. You can't feel it. It causes no pain, no discharge,” Giuliano said. “The only way you can detect a cancer like that is with breast cancer screening. And those cancers are the smallest cancers—the cancers that are the easiest to cure.”

Giuliano was able to perform a breast-sparing therapy known as a partial mastectomy or lumpectomy.

“We remove the area of the breast that has cancer, all the way around so that we have clean margins,” Giuliano said. “And then we do an internal reconstruction to make the breast look as natural as possible.”

Giuliano also performed a procedure he pioneered, which he continues to develop at Cedars-Sinai, called a sentinel lymph node biopsy, removing one or two lymph nodes to be certain the cancer had not spread beyond the breast.

“He did such a beautiful job that if you were to look at my breast, you would not know I had had surgery,” Linda said.

Linda’s cancer was an infiltrating ductal carcinoma, a cancer that starts in the breast ducts and can spread throughout the body. It was also HER2 positive, so it required further treatment.

“Around 20% of cancers have this overexpression of the HER2 protein, which makes them more aggressive and at higher risk of spreading,” said medical oncologist Philomena McAndrew, MD. “For this reason, after Linda’s surgery we treated her with chemotherapy and immunotherapy. We followed that with radiation therapy, and Linda did incredibly well throughout each of these steps.”

One important element for Linda was McAndrew’s recommendation to use a cooling cap to help avoid hair loss during chemotherapy.

“I'm so thrilled that I did,” Linda said. “Dr. McAndrew told me that when women lose their hair, it's very traumatic. When they look in the mirror, they realize how sick they are. Fortunately, that didn’t happen to me, and I was so grateful.”

Linda completed her final radiation treatment in January and will continue preventive therapy for five years. She and Philip will also have regular follow-up screenings.

But for now they are headed from their “city house” in Culver City to their main house in Lake Arrowhead, to spend time with friends they haven’t seen in a while.

Then they’ll continue their journey, in sickness and in health, together.

“We’re going on a cruise to Hawaii at the end of February,” Linda said. “We're just trying to pack some fun into the next 20 years.”

Cedars-Sinai Health Sciences University is advancing groundbreaking research and educating future leaders in medicine, biomedical sciences and allied health sciences. Learn more about the university.

As a highlight of the symposium, Armando E. Giuliano, MD, division director of Breast Surgical Oncology in the Jim and Eleanor Randall Department of Surgery at Cedars-Sinai, will receive the William L. McGuire Memorial Lecture Award in recognition of his significant contributions to the field of breast cancer research.

“It is a great honor to receive the 2025 McGuire Award,” Giuliano said. “We’ve made tremendous progress in the surgical treatment of this disease, and I am especially grateful to the brave patients who participated in the trials that helped us develop new standards of care and improve the lives of patients with early metastatic breast cancer.”

Giuliano was instrumental in refining sentinel lymph node biopsy for breast cancer in the early 1990s, sparing many women from more invasive breast cancer surgery. This technique identifies and removes only the first lymph node where cancer is most likely to spread to determine whether removing additional nodes is medically necessary.

Through two large multicenter trials, ACOSOG Z0010 and ACOSOG Z0011, Giuliano and team validated the technique that led to establishing the less-invasive sentinel lymph node biopsy as the standard of care, as opposed to axillary lymph node dissection, which removed most or all nodes and is associated with increased surgical complications. The findings from these trials transformed surgical management of breast cancer.

“The pioneering contributions Dr. Giuliano has made to breast oncology have not only changed the field, but they have directly and positively impacted the lives of millions of women worldwide,” said Cristina Ferrone, MD, chair of the Department of Surgery at Cedars-Sinai. “It is a privilege to work alongside Dr. Giuliano, and I wholeheartedly congratulate him on this well-deserved honor.”

Giuliano, the Linda and Jim Lippman Chair in Surgical Oncology, associate director of the Samuel Oschin Comprehensive Cancer Institute and co-director of the Saul and Joyce Brandman Breast Center—A Project of Women’s Guild, will present his award lecture on Wednesday, Dec. 10, at 9 a.m. CT.

Additional Cedars-Sinai experts attending the meeting:

Yuan Yuan, MD, PhD, director of Breast Oncology and medical director of Breast Cancer Research, will present data on how patient-derived organoids—tiny groups of cells—can guide therapy in patients with metastatic breast cancer. She also will present research on AI-driven H&E slides predicting triple-negative breast cancer patients’ response to therapy, as well as data from an ongoing clinical trial of a novel PD1-VEGF bispecific antibody for early-stage triple-negative breast cancer.

Stephen Shiao, MD, PhD, professor of Radiation Oncology and radiation oncology director of the Breast Oncology Disease Research Group, will participate in a plenary talk regarding a randomized trial of no-, low- or high-dose preoperative radiation with pembrolizumab and chemotherapy in node-positive, HER2-negative breast cancer. He can also discuss the potential of GLP-1 receptor agonists in combination with radiotherapy to improve overall survival in triple-negative breast cancer. Luxi Chen, MD, who will present a poster detailing this research at the conference, is a recipient of a San Antonio Breast Cancer Symposium Young Investigator Award.

Scheduling interviews:

To schedule an interview with a Cedars-Sinai expert, please contact:

Jillian Scholten | 949-244-2561 | jillian.scholten@cshs.org

Read more in Cedars-Sinai Discoveries: Abreast of Trends in Cancer

Most breast cancer cases in the U.S. are considered to be early stage, meaning they’re diagnosed before the disease has spread beyond the breast and surrounding (axillary) lymph nodes.

Giuliano, co-director of the Saul and Joyce Brandman Breast Center—A Project of Women’s Guild at Cedars-Sinai Cancer, led earlier studies of sentinel lymph node biopsy, in which only a few lymph nodes closest to the breast (sentinel nodes) are removed and examined to determine if the disease has spread.

“We’ve proven that if the sentinel node is negative (no cancer), 99% of the time the cancer has not spread elsewhere in the body,” he told Everyday Health.

The new lymph node study, which did not involve Giuliano, found that it also was not necessary to remove a large number of axillary lymph nodes if the sentinel node biopsy indicated the cancer had spread.

Giuliano, who holds the Linda and Jim Lippman Chair in Surgical Oncology, told Everyday Health that breast cancer patients often are reluctant to remove axillary lymph nodes because it can cause complications.

“Some women get terrible arm swelling from lymphedema,” Giuliano said. “You can have shoulder problems, such as a limited range of motion, numbness and pain that can be chronic and persist long-term. These problems are very difficult to manage.”

He told Everyday Health that women with early-stage breast cancer who are advised by their physician to have axillary lymph nodes removed should pause and carefully consider the recommendation.

“Get a second opinion,” he said.

Click here to read the complete article from Everyday Health.